
Fériel Marin was appointed in 2026 as Chief Quality Officer ad interim to ensure continuity during the transition between the retirement of Mr. Christophe Ancel, the current Quality Director, and the arrival of the Company’s new Quality Director. An engineer by training and a graduate of the Strasbourg School of Management, she began her career in the pharmaceutical industry at Merck Millipore, Anapharm Montréal, and later at Lilly. She joined Transgene in 2007 as Quality Manager and was appointed GMP Quality Director in 2023. In this role, Fériel Marin has led the evolution of the Company’s Quality System, strengthened operational standards, and supported teams in a constantly changing regulatory environment.